Xbrane Biopharma: Capital raise and Ximluci Q1 sales - Redeye
Redeye positively views yesterday's press release, which included a SEK350m capital injection and the first preliminary sales figures from Ximluci in Q1. We also leave our comments.
ANNONS
Redeye positively views yesterday's press release, which included a SEK350m capital injection and the first preliminary sales figures from Ximluci in Q1. We also leave our comments.